This inventor holds 6 USPTO granted patents. Top assignees: Mitsubishi Tanabe Pharma Corporation, K.K. Bcj-94. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: Innovations of Yukiko Nishimura
Introduction
Yukiko Nishimura is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of oxidative stress diseases. With a total of three patents to her name, her work is recognized for its innovative approaches to medication administration.
Latest Patents
One of her latest patents is a pharmaceutical composition for the oral administration of edaravone. This method involves administering the composition to a subject in need, with specific time intervals after meal consumption. The time intervals are designed to optimize the effectiveness of the treatment, being 8 hours or longer after a high-fat meal, 4 hours or longer after a standard meal, or 2 hours or longer after a light meal. This innovative approach aims to enhance the therapeutic outcomes for patients suffering from oxidative stress diseases.
Career Highlights
Yukiko Nishimura is currently associated with Mitsubishi Tanabe Pharma Corporation, where she continues to advance her research and development efforts. Her work has been instrumental in creating effective pharmaceutical solutions that address critical health issues.
Collaborations
Yukiko has collaborated with notable colleagues, including Hidetoshi Shimizu and Yoshinobu Nakamaru. Their combined expertise has contributed to the success of various projects within the pharmaceutical sector.
Conclusion
Yukiko Nishimura's innovative contributions to the field of pharmaceuticals highlight her dedication to improving patient care through effective treatment methods. Her work continues to inspire advancements in medical science and offers hope for those affected by oxidative stress diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
